Bruker Corporation ( BRKR Quick Quote BRKR - Free Report) recently announced the expansion of the fundamental research infrastructure in the United Kingdom, with two new orders of 1.2 GHz Avance nuclear magnetic resonance (NMR) spectrometers. The products will be delivered to the University of Warwick and the University of Birmingham.
The novel 1.2 GHz NMR spectrometer, which belongs to the company’s BioSpin group, enables advanced research in life science, batteries, biofuels and renewable energy.
By purchasing Bruker’s NMR spectrometer, the University of Warwick will advance its research capabilities in improved plant biofuels, batteries, and solar cells by studying molecular structures and the dynamics of advanced materials. The scientific insights gained will aid in improving the efficiency and durability of renewable energy technologies, and developing new materials.
Per management at the university, connecting the new 1.2 GHz spectrometer with the 850 MHz and 1 GHz systems of the UK High-Field Solid-State NMR Facility will enable scientists to continue making progress in diverse fields, from batteries and catalysts to pharmaceuticals and plant biomass.
Image Source: Zacks Investment Research
Meanwhile, the University of Birmingham will utilize the increased sensitivity and resolution of 1.2 GHz NMR to advance research in functional and structural biology and drug discovery. The ability of NMR to deal with dynamics and disorder plays a key role in understanding molecular mechanisms in health and disease contexts.
Researchers will study the structure, function, interactions and pathways of proteins and other biomolecules. They will also examine the structure of enzymes involved in antibiotic resistance, which could potentially help develop new antibiotics.
The system installations are expected to commence in 2025 and will be accessible to all scientists across the country. However, the same will be available to students once the research phase begins.
Industry Prospects Per a Research report, the global NMR spectroscopy market was valued at $690 million in 2022 and is expected to witness a CAGR of 5.1% by 2030.
The manufacturing of generic drugs is expected to boost the requirement for NMR spectroscopy in the market.
In March 2023, Bruker announced important bioinformatics launches for 4D-Proteomics on the timsTOF platform. A novel de novo sequencing algorithm was developed in collaboration with Rapid Novor Inc., which uses more than 1.7 million PASEF data points to improve accuracy and speed for immunopeptidomics in real time.
In the last month, Bruker announced the successful customer installations of two novel, compact 1.0 GHz NMR spectrometers for advanced structural and molecular biology applications. These compact ultra-high-field NMR systems are generating scientific data for functional, structural and molecular biology, and phenomics clinical research.
In the past six months, shares of the company have increased 40.7% compared with the
industry’s rise of 15.1%. Zacks Rank and Key Picks
Bruker Corporation currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the overall healthcare sector are
Haemonetics Corporation ( HAE Quick Quote HAE - Free Report) , TerrAscend Corp. and Akerna Corp. ( KERN Quick Quote KERN - Free Report) . Haemonetics and TerrAscend each sport a Zacks Rank #1 (Strong Buy) while Akerna carries a Zack Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here .
Haemonetics’ stock has risen 37.8% in the past year. Earnings estimates for Haemonetics have increased from $2.91 per share to $2.94 for 2023, and from $3.28 per share to $3.29 for 2024 in the past 30 days.
HAE’s earnings beat estimates in all the last four quarters, delivering an average surprise of 10.98%. In the last reported quarter, it reported an earnings surprise of 7.59%.
Estimates for TerrAscend in 2023 have decreased from a loss of 10 cents per share to a loss of 8 cents per share in the past 30 days. Shares of TerrAscend have declined 73% in the past year.
TerrAscend’s earnings beat estimates in one of the last three quarters and missed the mark in the other two, the average negative surprise being 136.11%. In the last reported quarter, TRSSF delivered an earnings surprise of 216.67%.
Akerna’s stock has declined 96.8% in the past year. Its estimates for 2023 have remained constant at a loss of $1.91 per share over the past 30 days.
Akerna missed earnings estimates in all the last four quarters, delivering a negative earnings surprise of 15.49%, on average. In the last reported quarter, KERN delivered a negative earnings surprise of 13.33%.